Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician
Z Szekanecz, MH Buch, C Charles-Schoeman… - Nature Reviews …, 2024 - nature.com
Janus kinase (JAK) inhibitors, including tofacitinib, baricitinib, upadacitinib and filgotinib, are
increasingly used in the treatment of rheumatoid arthritis (RA). There has been debate about …
increasingly used in the treatment of rheumatoid arthritis (RA). There has been debate about …
[HTML][HTML] Managing cardiovascular and cancer risk associated with JAK inhibitors
Janus kinase inhibitors (JAKi) have enormous appeal as immune-modulating therapies
across many chronic inflammatory diseases, but recently this promise has been …
across many chronic inflammatory diseases, but recently this promise has been …
JAK inhibitor selectivity: new opportunities, better drugs?
A Virtanen, FR Spinelli, JB Telliez, JJ O'Shea… - Nature Reviews …, 2024 - nature.com
Cytokines function as communication tools of the immune system, serving critical functions
in many biological responses and shaping the immune response. When cytokine production …
in many biological responses and shaping the immune response. When cytokine production …
[HTML][HTML] ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical Practice
M Benucci, M Bardelli, M Cazzato, E Laurino… - Journal of Personalized …, 2023 - mdpi.com
Background: Filgotinib (FIL) is a selective JAK1 inhibitor with an affinity 30-fold higher than
JAK2, approved to treat moderate to severe active rheumatoid arthritis (RA), in adults with …
JAK2, approved to treat moderate to severe active rheumatoid arthritis (RA), in adults with …
[HTML][HTML] Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data
In this commentary, we review clinical data which helps inform individualized benefit–risk
assessment for tofacitinib in patients with psoriatic arthritis (PsA) and ankylosing spondylitis …
assessment for tofacitinib in patients with psoriatic arthritis (PsA) and ankylosing spondylitis …
[HTML][HTML] Efficacy and Safety of Filgotinib in Rheumatoid Arthritis Patients Aged over and under 65 Years (ENANTIA-65)
M Benucci, M Bardelli, M Cazzato, F Bartoli… - Journal of Personalized …, 2024 - mdpi.com
Background: According to recent data, the age of patients could represent an important risk
factor for MACE (major cardiovascular events), cancer, and VTE (venous thromboembolism) …
factor for MACE (major cardiovascular events), cancer, and VTE (venous thromboembolism) …
[HTML][HTML] How to treat a patient with psoriatic arthritis and chronic lymphocytic leukemia?
J Braun, K Karberg… - Exploration of …, 2024 - explorationpub.com
A 76-year-old male patient who has been suffering from psoriatic arthritis (PsA) for 15 years
was diagnosed with chronic lymphocytic leukemia (CLL) 18 months ago. He has been …
was diagnosed with chronic lymphocytic leukemia (CLL) 18 months ago. He has been …
[HTML][HTML] Multicenter evaluation of tofacitinib retention and safety in rheumatoid arthritis–why cardiovascular risk factors do not equate to overt risk
A Felis-Giemza, M Moskal, K Proc, Z Guzera… - …, 2023 - ncbi.nlm.nih.gov
Results Median (interquartile range) follow-up in the whole sample was 16.9 (5.93–31.7)
months. Mean (standard deviation) age was 51.44 (±11.84) years, with female …
months. Mean (standard deviation) age was 51.44 (±11.84) years, with female …